Cambridge Nutritional Sciences Plc

日前，Genesis Therapeutics公司宣布，与礼来（Eli Lilly and Company）达成合作，利用Genesis的人工智能（AI）药物发现平台，针对多个治疗领域的多达5个靶点发现创新疗法。 Genesis公司的分子AI平台结合了3D结构察觉深度神经网络，新型分子模拟手段，以及可大幅度扩展的分子生成引擎。该公司的技术尤其适合针对此前不可成药或者数据欠缺的靶点。该公司的首席执行官Evan Feinberg博士曾入选福布斯医疗健康“30 under 30”榜单。这家公司在2020年曾与基因泰克达成多靶点研发合作。 根据协议，Genesis和礼来的科学家将联合使用Genesis的AI药物发现平台，针对3个靶点开发潜在“first-in-class”和“best-in-class”候选药物。Genesis将获得2000万美元的前期付款，礼来具有添加两个额外靶点的选择权。Genesis有资格获得总计高达6.7亿美元的前期和里程碑付款。 “我们很高兴与礼来合作，为受到严重疾病困扰的患者发现创新药物。”Genesis首席执行官Evan Feinberg博士说，“在Genesis，由AI研究人员、软件工程师、化学家和生物学家构成的跨学科团队密切合作，拓展化学机器学习的边界，针对传统发现手段难解的靶点创造新疗法。我们期待联合各自组织的专长，解决关键领域的未竟医疗需求。” 参考资料： [1] Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform. Retrieved May 3, 2022, from https://www.businesswire.com/news/home/20220503005444/en/Genesis-Therapeutics-Announces-Strategic-Collaboration-with-Lilly-to-Discover-Novel-Therapies-Using-the-Genesis-Molecular-AI-Platform 内容来源于网络，如有侵权，请联系删除，谢谢。

Accubio Limited signed a conditional sale and purchase agreement to acquire Diagnostic Test kit Manufacturing Business and Facility in Alva, Scotland from Omega Diagnostics Group PLC (AIM:ODX) for £1 million on February 11, 2022. The consideration will be paid in cash on completion. The manufacturing business is being sold as a going concern with approximately 109 full-time employees based in Alva transferring across with the business, with no resultant redundancies. The Agreement also covers the sale of certain fixed assets, including plant and equipment (although not any Government-funded equipment on site), as well as the assignment of the lease for the Alva site. The sale will significantly reduce the Groups fixed cost base and eliminate a number of potential future liabilities, whilst generating funds for further investment and growth. The sale is conditional on, amongst other things, the execution of a comprehensive transitional services agreement in line with the principles which have been agreed, the consent of the landlord to assign the Alva lease and the Secretary of State for the Department of Business, Energy and Industrial Strategy not issuing a Public Interest Intervention Notice requiring a review of the Sale, in each case prior to March 7, 2022. Geoff Nash, Edward Whiley, George Dollemore, Alice Lane and Charlotte Sutcliffe of finnCap Ltd acted as financial advisors to Omega Diagnostics in the transaction. Accubio Limited completed the acquisition of Diagnostic Test kit Manufacturing Business and Facility in Alva, Scotland from Omega Diagnostics Group PLC (AIM:ODX) on March 7, 2022.